EP3448384A1 - Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them - Google Patents
Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing themInfo
- Publication number
- EP3448384A1 EP3448384A1 EP17726698.8A EP17726698A EP3448384A1 EP 3448384 A1 EP3448384 A1 EP 3448384A1 EP 17726698 A EP17726698 A EP 17726698A EP 3448384 A1 EP3448384 A1 EP 3448384A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- complex
- ivacaftor
- lumacaftor
- pharmaceutical combination
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 362
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 73
- 238000000034 method Methods 0.000 title claims abstract description 66
- 229940052950 ivacaftor and lumacaftor Drugs 0.000 title claims abstract description 33
- 150000003839 salts Chemical class 0.000 title claims abstract description 13
- 238000009472 formulation Methods 0.000 title claims description 199
- 230000008569 process Effects 0.000 title claims description 52
- 238000002360 preparation method Methods 0.000 title claims description 14
- 230000035699 permeability Effects 0.000 claims abstract description 46
- 239000002245 particle Substances 0.000 claims abstract description 30
- 238000004090 dissolution Methods 0.000 claims abstract description 27
- 230000009246 food effect Effects 0.000 claims abstract description 26
- 235000021471 food effect Nutrition 0.000 claims abstract description 26
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 230000001404 mediated effect Effects 0.000 claims abstract description 15
- PURKAOJPTOLRMP-UHFFFAOYSA-N ivacaftor Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 claims description 231
- 229960004508 ivacaftor Drugs 0.000 claims description 223
- UFSKUSARDNFIRC-UHFFFAOYSA-N lumacaftor Chemical compound N1=C(C=2C=C(C=CC=2)C(O)=O)C(C)=CC=C1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 UFSKUSARDNFIRC-UHFFFAOYSA-N 0.000 claims description 200
- 229960000998 lumacaftor Drugs 0.000 claims description 199
- 239000000243 solution Substances 0.000 claims description 107
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 75
- 239000007864 aqueous solution Substances 0.000 claims description 54
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 50
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 49
- 229920001577 copolymer Polymers 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 45
- 229940117958 vinyl acetate Drugs 0.000 claims description 44
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 40
- 239000008187 granular material Substances 0.000 claims description 40
- 229910001868 water Inorganic materials 0.000 claims description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- 238000002156 mixing Methods 0.000 claims description 36
- 238000013149 parallel artificial membrane permeability assay Methods 0.000 claims description 33
- 239000008139 complexing agent Substances 0.000 claims description 30
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 29
- 229920001983 poloxamer Polymers 0.000 claims description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 26
- 239000007787 solid Substances 0.000 claims description 25
- 239000006185 dispersion Substances 0.000 claims description 24
- 229960000502 poloxamer Drugs 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 229910016860 FaSSIF Inorganic materials 0.000 claims description 18
- 229910005429 FeSSIF Inorganic materials 0.000 claims description 18
- 239000000084 colloidal system Substances 0.000 claims description 18
- -1 poly(2-ethyl-2-oxazoline) Polymers 0.000 claims description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 238000010668 complexation reaction Methods 0.000 claims description 15
- 201000009266 primary ciliary dyskinesia Diseases 0.000 claims description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 13
- 239000002202 Polyethylene glycol Substances 0.000 claims description 13
- 238000001069 Raman spectroscopy Methods 0.000 claims description 13
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 13
- 208000025678 Ciliary Motility disease Diseases 0.000 claims description 12
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 230000007812 deficiency Effects 0.000 claims description 12
- 201000010064 diabetes insipidus Diseases 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 10
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 8
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
- 206010067265 Heterotaxia Diseases 0.000 claims description 6
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 6
- 206010033645 Pancreatitis Diseases 0.000 claims description 6
- 208000031733 Situs inversus totalis Diseases 0.000 claims description 6
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 208000008797 situs inversus Diseases 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 5
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
- 239000011976 maleic acid Substances 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 239000011877 solvent mixture Substances 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 claims description 4
- 239000012861 aquazol Substances 0.000 claims description 4
- 229920006187 aquazol Polymers 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- 229960004106 citric acid Drugs 0.000 claims description 4
- 150000005690 diesters Chemical class 0.000 claims description 4
- 125000005456 glyceride group Chemical group 0.000 claims description 4
- 229920000578 graft copolymer Polymers 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 claims description 4
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims description 4
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 4
- 239000011118 polyvinyl acetate Substances 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 102100034452 Alternative prion protein Human genes 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 102100032187 Androgen receptor Human genes 0.000 claims description 3
- 208000009575 Angelman syndrome Diseases 0.000 claims description 3
- 206010002961 Aplasia Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 208000012904 Bartter disease Diseases 0.000 claims description 3
- 208000010062 Bartter syndrome Diseases 0.000 claims description 3
- 208000006386 Bone Resorption Diseases 0.000 claims description 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 208000031976 Channelopathies Diseases 0.000 claims description 3
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 3
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 206010062264 Congenital hyperthyroidism Diseases 0.000 claims description 3
- 206010010774 Constipation Diseases 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 208000024940 Dent disease Diseases 0.000 claims description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 3
- 206010013883 Dwarfism Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 208000024720 Fabry Disease Diseases 0.000 claims description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 3
- 208000019683 Gorham-Stout disease Diseases 0.000 claims description 3
- 206010019860 Hereditary angioedema Diseases 0.000 claims description 3
- 208000033981 Hereditary haemochromatosis Diseases 0.000 claims description 3
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 claims description 3
- 201000000101 Hyperekplexia Diseases 0.000 claims description 3
- 206010058271 Hyperexplexia Diseases 0.000 claims description 3
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims description 3
- 206010051125 Hypofibrinogenaemia Diseases 0.000 claims description 3
- 208000000038 Hypoparathyroidism Diseases 0.000 claims description 3
- 208000003892 Kartagener syndrome Diseases 0.000 claims description 3
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 208000007466 Male Infertility Diseases 0.000 claims description 3
- 208000029725 Metabolic bone disease Diseases 0.000 claims description 3
- 208000008955 Mucolipidoses Diseases 0.000 claims description 3
- 206010072928 Mucolipidosis type II Diseases 0.000 claims description 3
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims description 3
- 208000010316 Myotonia congenita Diseases 0.000 claims description 3
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 3
- 206010049088 Osteopenia Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 208000035467 Pancreatic insufficiency Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 208000025237 Polyendocrinopathy Diseases 0.000 claims description 3
- 108091000054 Prion Proteins 0.000 claims description 3
- 208000024777 Prion disease Diseases 0.000 claims description 3
- 201000005660 Protein C Deficiency Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 208000035954 Thomsen and Becker disease Diseases 0.000 claims description 3
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 3
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 3
- 208000004622 abetalipoproteinemia Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 230000002146 bilateral effect Effects 0.000 claims description 3
- 230000010256 bone deposition Effects 0.000 claims description 3
- 230000008468 bone growth Effects 0.000 claims description 3
- 230000010478 bone regeneration Effects 0.000 claims description 3
- 230000024279 bone resorption Effects 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 208000007451 chronic bronchitis Diseases 0.000 claims description 3
- 210000004081 cilia Anatomy 0.000 claims description 3
- 230000001886 ciliary effect Effects 0.000 claims description 3
- 230000000112 colonic effect Effects 0.000 claims description 3
- 230000007547 defect Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims description 3
- 230000035876 healing Effects 0.000 claims description 3
- 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 claims description 3
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 108010040003 polyglutamine Proteins 0.000 claims description 3
- 229920000155 polyglutamine Polymers 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 230000020978 protein processing Effects 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 230000001603 reducing effect Effects 0.000 claims description 3
- 230000008439 repair process Effects 0.000 claims description 3
- 201000009890 sinusitis Diseases 0.000 claims description 3
- 239000000779 smoke Substances 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 210000001177 vas deferen Anatomy 0.000 claims description 3
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 claims description 2
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 2
- 229920002675 Polyoxyl Polymers 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 2
- 229960003964 deoxycholic acid Drugs 0.000 claims description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 2
- 239000013022 formulation composition Substances 0.000 claims description 2
- 229940072106 hydroxystearate Drugs 0.000 claims description 2
- 229960003194 meglumine Drugs 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 229960004249 sodium acetate Drugs 0.000 claims description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims description 2
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 claims 4
- 239000003125 aqueous solvent Substances 0.000 claims 1
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 abstract description 17
- 238000004519 manufacturing process Methods 0.000 abstract description 16
- 150000001875 compounds Chemical class 0.000 abstract description 9
- 239000000843 powder Substances 0.000 description 31
- 239000007788 liquid Substances 0.000 description 25
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 18
- 238000001694 spray drying Methods 0.000 description 15
- 239000007962 solid dispersion Substances 0.000 description 14
- YQCGOSZYHRVOFW-UHFFFAOYSA-N n-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1h-quinoline-3-carboxamide;3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid Chemical compound C1=C(O)C(C(C)(C)C)=CC(C(C)(C)C)=C1NC(=O)C1=CNC2=CC=CC=C2C1=O.N1=C(C=2C=C(C=CC=2)C(O)=O)C(C)=CC=C1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 YQCGOSZYHRVOFW-UHFFFAOYSA-N 0.000 description 13
- 239000003826 tablet Substances 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 238000001228 spectrum Methods 0.000 description 10
- 229940080152 orkambi Drugs 0.000 description 9
- 230000003993 interaction Effects 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 229940005405 kalydeco Drugs 0.000 description 7
- 238000004088 simulation Methods 0.000 description 7
- 229920002517 Poloxamer 338 Polymers 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000007908 dry granulation Methods 0.000 description 6
- FYUWIEKAVLOHSE-UHFFFAOYSA-N ethenyl acetate;1-ethenylpyrrolidin-2-one Chemical compound CC(=O)OC=C.C=CN1CCCC1=O FYUWIEKAVLOHSE-UHFFFAOYSA-N 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 238000005469 granulation Methods 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002304 perfume Substances 0.000 description 6
- 238000009725 powder blending Methods 0.000 description 6
- 238000004007 reversed phase HPLC Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000001237 Raman spectrum Methods 0.000 description 5
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000007922 dissolution test Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000003801 milling Methods 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000005056 compaction Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229940032007 methylethyl ketone Drugs 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 238000009491 slugging Methods 0.000 description 4
- 238000007711 solidification Methods 0.000 description 4
- 230000008023 solidification Effects 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004606 Fillers/Extenders Substances 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 229940096516 dextrates Drugs 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 229960002160 maltose Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 229940044476 poloxamer 407 Drugs 0.000 description 3
- 229920001992 poloxamer 407 Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical compound O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 239000004377 Alitame Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 239000001329 FEMA 3811 Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004384 Neotame Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 235000010358 acesulfame potassium Nutrition 0.000 description 2
- 229960004998 acesulfame potassium Drugs 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000019409 alitame Nutrition 0.000 description 2
- 108010009985 alitame Proteins 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 238000012801 analytical assay Methods 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229960003563 calcium carbonate Drugs 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 229960001708 magnesium carbonate Drugs 0.000 description 2
- 235000014380 magnesium carbonate Nutrition 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 229960000869 magnesium oxide Drugs 0.000 description 2
- 235000012245 magnesium oxide Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 2
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 description 2
- 235000010434 neohesperidine DC Nutrition 0.000 description 2
- 235000019412 neotame Nutrition 0.000 description 2
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 2
- 108010070257 neotame Proteins 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 229960001462 sodium cyclamate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000012798 spherical particle Substances 0.000 description 2
- 238000010922 spray-dried dispersion Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000000892 thaumatin Substances 0.000 description 2
- 235000010436 thaumatin Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 229940074410 trehalose Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 229910007261 Si2N3 Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 231100001125 band 2 compound Toxicity 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000013561 fixed dose combination tablet Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000021400 peanut butter Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000001392 ultraviolet--visible--near infrared spectroscopy Methods 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the invention is directed to a pharmaceutical composition comprising stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Ivacaftor and Lumacaftor, their salts, or derivatives thereof, which is useful in the treatment of cystic fibrosis transmembrane conductance regulator (CFTR) mediated disease.
- the pharmaceutical composition comprising the complexes of the present invention possess instantaneous redispersibility, increased apparent solubility and permeability, no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form.
- the invention also relates to methods of formulating and manufacturing complexes according to the invention, pharmaceutical compositions containing it, its uses and methods of treatment using the complex and its compositions.
- Ivacaftor The active ingredient in KALYDECO® tablets is Ivacaftor, which has the following chemical name: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-l,4-dihydro-4oxoquinoline-3-carboxamide. Its molecular formula is C 24 H 28 N 2 0 3 and its molecular weight is 392.49. Ivacaftor has the following structural formula:
- Ivacaftor is a white to off-white powder that is practically insoluble in water ( ⁇ 0.05 microgram/mL). Due to poor aqueous solubility, extensive formulation efforts were required and resulted in a spray-dried dispersion of Ivacaftor suitable for oral administration.
- KALYDECO® containing the spray-dried dispersion of Ivacaftor is available as a light blue capsule-shaped, film- coated tablet for oral administration containing 150 mg of Ivacaftor.
- Each tablet contains the inactive ingredients colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate.
- the tablet film coat contains carnauba wax, FD&C Blue #2, PEG 3350, polyvinyl alcohol, talc, and titanium dioxide.
- the printing ink contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac.
- Ivacaftor is a potentiator of the CFTR protein.
- the CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Ivacaftor facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein.
- KALYDECO® should be administered with fat-containing food.
- fat-containing foods include eggs, butter, peanut butter, and cheese pizza.
- the median (range) t max is approximately 4.0 (3.0; 6.0) hours in the fed state.
- Ivacaftor is extensively metabolized in humans. In-vitro and clinical studies indicate that Ivacaftor is primarily metabolized by CYP3A. Ml and M6 are the two major metabolites of Ivacaftor in humans. Ml has approximately one-sixth the potency of Ivacaftor and is considered pharmacologically active. M6 has less than one-fiftieth the potency of Ivacaftor and is not considered pharmacologically active. [009] Following oral administration, the majority of Ivacaftor (87.8%) is eliminated in the feces after metabolic conversion.
- the major metabolites Ml and M6 accounted for approximately 65% of the total dose eliminated with 22% as Ml and 43% as M6. There was negligible urinary excretion of Ivacaftor as unchanged parent. The apparent terminal half-life was approximately 12 hours following a single dose.
- the mean apparent clearance (CL/F) of Ivacaftor was similar for healthy subjects and patients with CF.
- the CL/F (SD) for the 150 mg dose was 17.3 (8.4) L/hr in healthy subjects.
- Lumacaftor is one of the active ingredients in ORKAMBI® tablets, which has the following chemical name: 3-[6-( ⁇ [l-(2,2-difluoro-l,3-benzodioxol-5- yl)cyclopropyl]carbonyl ⁇ amino)-3-methylpyridin-2-yl]benzoic acid.
- the molecular formula for lumacaftor is C 2 4H 18 F 2 N 2 0 5 .
- the molecular weight for Lumacaftor is 452.41.
- the structural formula is:
- Lumacaftor is a white to off-white powder that is practically insoluble in water (0.02 mg/mL).
- ORKAMBI® is available as a pink, oval-shaped, film-coated tablet for oral administration containing 200 mg of Lumacaftor and 125 mg of Ivacaftor.
- Each ORKAMBI® tablet contains 200 mg of Lumacaftor and 125 mg of Ivacaftor, and the following inactive ingredients: cellulose, microcrystalline; croscarmellose sodium; hypromellose acetate succinate; magnesium stearate; povidone; and sodium lauryl sulfate.
- the tablet film coat contains carmine, FD&C Blue #1, FD&C Blue #2, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.
- the printing ink contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac.
- Lumacaftor improves the conformational stability of F508del-CFTR, resulting in increased processing and trafficking of mature protein to the cell surface. ln-vitro studies have demonstrated that Lumacaftor acts directly on the CFTR protein in primary human bronchial epithelial cultures and other cell lines harboring the F508del-CFTR mutation to increase the quantity, stability, and function of F508del-CFTR at the cell surface, resulting in increased chloride ion transport.
- Lumacaftor Following multiple oral dose administrations of Lumacaftor, the exposure of Lumacaftor increased roughly proportionally with dose from 50 to 1000 mg qd. In subjects with CF, the Lumacaftor C max and AUC also increases approximately proportional with the dose over the Lumacaftor 25 mg qd to 400 mg ql2h dose range. The exposure of Lumacaftor increased approximately 1.6-to 2.0-fold when given with fat containing food. The median (range) time of the maximum concentration (t ⁇ ) is approximately 4.0 (2.0, 9.0) hours in the fed state.
- Lumacaftor is approximately 99% bound to plasma proteins, primarily to albumin. After oral administration of 200 mg every 24 hours for 28 days to patients with cystic fibrosis (CF) in a fed state, the mean (+SD) for apparent volumes of distribution was 86.0 (69.8) L.
- Lumacaftor The half-life of Lumacaftor is approximately 26 hours in patients with CF.
- the typical apparent clearance, CL/F (CV), of Lumacaftor was estimated to be 238 L/hr (29.4%) for patients with CF.
- CL/F (CV) The typical apparent clearance, CL/F (CV)
- Lumacaftor is not extensively metabolized in humans with the majority (51%) of Lumacaftor excreted unchanged in the feces. There was minimal elimination of Lumacaftor and its metabolites in urine (only 8.6% of total radioactivity was recovered in the urine with 0.18% as unchanged parent). In -vitro and in vivo data indicate that Lumacaftor is mainly metabolized via oxidation and glucuronidation.
- Lumacaftor has low aqueous solubility and high permeability assessed via the colorectal adenocarcinoma (Caco-2) cell system. Although pH-dependent solubility was observed, the Lumacaftor drug substance is practically insoluble in water and buffer solutions of pH 1.0 to pH 8.0. Therefore, Lumacaftor is suggested to be a BCS Class 2 (low solubility/high permeability) compound. [0019] Since Lumacaftor is considered a BCS class II, the drug substance was jet-milled early in development to reduce the particle size and potentially improve bioavailability. Based on these studies a control on Lumacaftor particle size in the drug substance specification was established.
- Lumacaftor alone and in combination which includes suspension, capsules and tablets. Comparative exposure of the different formulations of Lumacaftor was seen in single dose studies in healthy volunteers. Exposure of the suspension is lower than that seen for capsules and tablets. Early clinical studies were conducted with the co-administration of both Ivacaftor and Lumacaftor. A cross-over study (007) was conducted to evaluate the relative bioavailability of the fixed dose combination tablet as compared to the separate tablets.
- the tablet and FDC appear to be bioequivalent, and the only parameter that did not meet standard bioequivalence criteria is the Cmax of Ivacaftor (GLSMR [90% CI] - 1.20 [1.09, 1.33]). However, for practical purposes this is acceptable and the PK results from tablet formulation can be considered applicable to the FDC as well.
- Lumacaftor exposure was approximately 2 times higher and Ivacaftor exposure was approximately 3 times higher than when taken in a fasting state.
- Lumacaftor Following multiple oral dose administration of Lumacaftor in combination with Ivacaftor, the exposure of Lumacaftor generally increased proportional to dose over the range of 200 mg every 24 hours to 400 mg every 12 hours.
- the median (range) of Lumacaftor is approximately 4.0 hours (2.0; 9.0) in the fed state.
- the exposure of Ivacaftor Following multiple oral dose administration of Ivacaftor in combination with Lumacaftor, the exposure of Ivacaftor generally increased with dose from 150 mg every 12 hours to 250 mg every 12 hours.
- the median (range) t max of ivacaftor is approximately 4.0 hours (2.0; 6.0) in the fed state.
- novel pharmaceutical composition comprising complex formulations of Ivacaftor or its salts or its derivatives thereof and complexation agents and pharmaceutically acceptable excipients and complex formulations of Lumacaftor or its salts or its derivatives thereof and complexation agents and pharmaceutically acceptable excipients were prepared.
- Novel pharmaceutical composition of the present invention is characterized by instantaneous redispersibility, increased apparent solubility, instantaneous dissolution, increased apparent permeability that exhibits no food effect which allows the precise dosing the active ingredients.
- a pharmaceutical combination composition with improved physicochemical characteristics and enhanced biological performance comprising i. complex Ivacaftor formulation or its pharmaceutical composition; and ii. complex Lumacator formulation or its pharmaceutical composition; and iii. optionally, pharmaceutically acceptable excipients; wherein said complex Ivacaftor formulation or its pharmaceutical composition comprising i. Ivacaftor, or a salt or derivative thereof; ii.
- At least one complexing agent chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), copolymers of vinylpyrrolidone and vinyl acetate, poly(2-ethyl-2-oxazoline), polyvinylpyrrolidone, poly(maleic acid/methyl vinyl ether), polyvinyl caprolactam- polyvinyl acetate -polyethylene glycol graft copolymer, ethylene oxide/propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate; and in.
- complexing agent chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of
- said complex Lumacaftor formulation or its pharmaceutical composition comprises i. Lumacaftor, or a salt or derivative thereof; ii. at least one complexation agent chosen from polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol, hydroxypropylcellulose, poloxamers (copolymers of ethylene oxide and propylene oxide blocks), vinylpyrrolidone/vinyl acetate copolymer, poly(2-ethyl-2-oxazoline), polyvinylpyrrolidone, poly(maleic acid/methyl vinyl ether), polyvinyl caprolactam- polyvinyl acetate -polyethylene glycol graft copolymer, polyoxyl 15 hydroxystearate, ethylene oxide/propylene oxide tetra functional block copolymer, and d-alpha tocopheryl polyethylene glycol 1000 succinate; and ii
- complex formulations or their pharmaceutical combination compositions have particle size between 10 nm and 600 nm, and the said pharmaceutical combination composition possesses at least one of following features: a) is instantaneously redispersable in physiological relevant media; b) is stable in solid form and in colloid solution and/ or dispersion; c) complex Ivacaftor and complex Lumacaftor formulations or their pharmaceutical composition have an apparent solubility in water of at least 1 mg/ mL; d) complex Ivacaftor and complex Lumacaftor formulations or their pharmaceutical compositions have a PAMPA permeability of at least 0.2* 10 "6 cm/s for Ivacaftor and 2* 10 ⁇ 6 cm/s for Lumacaftor when dispersed in FaSSIF or FeSSIF biorelevant media, which does not decrease in time for at least 6 month; e) has increased dissolution rate: 80 % of Ivacaftor and 80% of Lumaca
- the pharmaceutical combination composition according to Point 1 wherein the complexing agent of complex Ivacaftor formulation is a copolymer of vinylpyrrolidone and vinylacetate and optionally a poloxamer; and the complexing agent of complex Lumacaftor formulation is a copolymer of vinylpyrrolidone and vinylacetate.
- composition according to Point 1 wherein said pharmaceutically acceptable excipient of said complex Ivacaftor and complex Lumacaftor formulations is chosen from sodium deoxycholate, dioctyl sodium sulfosuccinate, sodium acetate, cetylpyridinium chloride, citric acid, meglumine and sodium lauryl sulfate.
- the pharmaceutical combination composition according to Point 10 wherein said pharmaceutically acceptable excipient is sodium lauryl sulfate.
- 12. The pharmaceutical combination composition according to Point 1 comprising i. complex Ivacaftor formulation; and ii. complex Lumacaftor formulation; and iii. optionally, pharmaceutically acceptable excipients; wherein said complex Ivacaftor formulation comprising i. Ivacaftor; ii. copolymer of vinylpyrrolidone and vinylacetate and optionally a poloxamer as complexing agents; and iii.
- said complex Ivacaftor formulation is characterized by infrared (ATR) peaks 588 cm 4 , 628 cm 1 , 767 cm 1 , 842 cm 1 , 962 cm 1 , 1019 cm 1 , 1108 cm 1 , 1148 cm 1 , 1240 cm 1 , 1343 cm 1 , 1370 cm 1 , 1425 cm 1 , 1465 cm 1 , 1525 cm 1 , 1567 cm 1 , 1666 cm 4 and 1732 cm 1 ; and is characterized by Raman shifts at 552 cm 1 , 648 cm 1 , 826 cm 1 , 845 cm 4 , 888 cm 1 , 932 cm 4 , 1026 cm 1 , 1062 cm 1 , 1082 cm 1 , 1129 cm , 1140 cm 1 , 1208 cm 1 , 1233 cm 1 , 1262 cm 1 , 1284 cm 1 , 1295 cm 1 , 1361 cm 1 , 1450 cm
- ATR infrared
- Lumacaftor ii. copolymer of vinylpyrrolidone and vinylacetate as complexing agent; and iii. sodium lauryl sulfate as an excipient; wherein said complex Lumacaftor formulations is characterized by infrared (ATR) peaks at 635 cm 1 , 703 cm 1 , 747 cm 1 , 837 cm 1 , 1021 cm 1 , 1165 cm 1 , 1231 cm 1 , 1288 cm 4 , 1369 cm 4 , 1423 cm 4 , 1462 cm 4 , 1494 cm 4 , 1667 cm 4 and 1731 cm 4 ; and is characterized by Raman shifts at 553 cm 4 , 602 cm , 635 cm 4 , 654 cm , 747 cm , 841 cm 4 , 899 cm 4 , 934 cm , 1002 cm , 1021 cm 4 , 1117 cm , 1205 cm , 1232 cm 4 , 1310 cm , 1352 cm 4 , 13
- a pharmaceutical combination composition to either of Point 1 or Point 12 comprising complex Ivacaftor formulation or its pharmaceutical composition and complex Lumacaftor formulation or its pharmaceutical composition in a total amount ranging from about 10.0 weight % to 100.0 weight % based on the total weight of the pharmaceutical composition.
- a pharmaceutical combination composition to either of Point 1 or Point 12 comprising complex Ivacaftor formulation or its pharmaceutical composition and complex Lumacaftor formulation or its pharmaceutical composition in a total amount ranging from about 50.0 weight % to 100.0 weight % based on the total weight of the pharmaceutical composition.
- a process for the preparation of the complexes of Ivacaftor according to Point 1 comprising the step of mixing a pharmaceutically acceptable solution containing
- Ivacaftor and complexing agents which is a copolymer of vinylpyrrolidone and vinylacetate and optionally a poloxamer with an aqueous solution containing at least one pharmaceutically acceptable excipient which is sodium lauryl sulfate.
- a process for the preparation of the complexes of Lumacaftor according to Point 1 comprising the step of mixing a pharmaceutically acceptable solution containing
- Lumacaftor, and complexing agent which is a copolymer of vinylpyrrolidone and vinylacetate with an aqueous solution containing at least one pharmaceutically acceptable excipient which is sodium lauryl sulfate.
- a pharmaceutical combination composition comprising the pharmaceutical combination composition according to Point 1 together with a pharmaceutically acceptable carrier.
- composition according to Point 25, wherein said pharmaceutical composition is suitable for oral, pulmonary, rectal, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, or topical administration.
- a method of treatment of CFTR mediated diseases comprising administration of a therapeutically effective amount of the pharmaceutical combination composition according to Point 1 or the pharmaceutical composition according to Point 25.
- a pharmaceutical combination composition comprising a mixture of: a) a stable complex Ivacaftor formulation; and b) a stable complex Lumacaftor formulation; and c) optionally, pharmaceutically acceptable excipients.
- the pharmaceutical combination composition of the present invention may additionally include one or more pharmaceutically acceptable excipients, auxiliary materials, carriers, active agents or combinations thereof.
- said pharmaceutical combination composition is suitable for oral administration.
- said pharmaceutical combination composition is suitable for oral administration as liquid dispersible granules in a sachet form.
- the daily human dose of said pharmaceutical combination composition can be adjusted based on the body weight by administering the pharmaceutical composition of the present invention in the required amount.
- said pharmaceutical combination composition can be administered orally from the age of 0.
- said complex formulations and said pharmaceutical composition are for use in the manufacture of a medicament for the treatment of CFTR mediated diseases.
- CFTR mediated disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseu
- a method of treatment of CFTR mediated diseases comprises administration of a therapeutically effective amount of complex formulations or their pharmaceutical combination compositions as described herein.
- said pharmaceutical composition further comprises one or more additional active agents.
- said additional active agent is chosen from agents used for the treatment of CFTR mediated diseases.
- said pharmaceutical composition comprising complex Ivacaftor formulation in combination with complex Lumacaftor formulation and optionally further pharmaceutically acceptable excipients characterized in that it possesses at least one of the following properties: a) is instantaneously redispersable in physiological relevant media; b) is stable in solid form and in colloid solution and/ or dispersion; c) complex Ivacaftor and/ or complex Lumacaftor formulations have an apparent solubility in water of at least 1 mg/mL; d) complex Ivacaftor and/ or complex Lumacaftor formulation have a PAMPA permeability of at least 0.2* 10 "6 cm/s for Ivacaftor and 2* 10 ⁇ 6 cm/s for Lumacaftor when dispersed in FaSSIF or FeSSIF biorelevant media, which does not decrease in time for at least 6 month;
- the complex Ivacaftor formulation used in the present invention comprises Ivacaftor; a complexing agent which is a copolymer of vinylpyrrolidone and vinylacetate and optionally a poloxamer; and sodium lauryl sulfate as a pharmaceutically acceptable excipient; said complexes characterized in that they possess at least one of the following properties: a) is instantaneously redispersable in physiological relevant media; b) is stable in solid form and in colloid solution and/ or dispersion; c) has an apparent solubility in water of at least 1 mg/ mL; d) has a PAMPA permeability of at least 0.2* 10 "6 cm/ s when dispersed in FaSSIF or FeSSIF biorelevant media, which does not decrease in time for at least 6 month; e) exhibits no observable food effect.
- a complexing agent which is a copolymer of vinylpyrrolidone and vinylacetate and optionally a poloxamer
- said Ivacaftor complex used in the present invention possesses at least two of the properties described in a)— e).
- said Ivacaftor complex used in the present invention possesses at least three of the properties described in a)— e).
- Ivacaftor formulations used in the present invention possess instantaneous redispersibility, increased apparent solubility and permeability, no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form. [0045]
- the expression Ivacaftor is generally used for Ivacaftor, or its salts or its derivatives.
- said complexation agent used in the Ivacaftor complex as used in the present invention is a copolymer of vinylpyrrolidone and vinylacetate and optionally a poloxamer.
- said complexation agent used in the Ivacaftor complex as used in the present invention is a copolymer of vinylpyrrolidone and vinylacetate.
- said copolymer of vinylpyrrolidone and vinylacetate has a 60:40 weight ratio of vinylpyrrolidone:vinyl acetate monomers.
- said poloxamer is poloxamer 338.
- said poloxamer is poloxamer 407.
- said pharmaceutically acceptable excipient used in the Ivacaftor complex as used in the present invention is sodium lauryl sulfate.
- the complexation agents used in the Ivacaftor complex as used in the present invention are copolymer of vinylpyrrolidone and vinyl acetate and poloxamer and said pharmaceutically acceptable excipient is sodium lauryl sulfate
- said Ivacaftor complex is characterized by infrared (ATR) spectrum having characteristic absorption peaks at 588 cm 1 , 628 cm 1 , 767 cm 1 , 842 cm 1 , 962 cm 1 , 1019 cm 1 , 1108 cm 1 , 1148 cm 1 , 1240 cm 1 , 1343 cm 1 , 1370 cm 1 , 1425 cm 1 , 1465 cm 1 , 1525 cm 1 , 1567 cm 1 , 1666 cm 4 and 1732 cm 4 ; and b) said Ivacaftor complex has characteristic Raman shifts at 552 cm 4 , 648 cm 4 , 826 cm 4 , 845 cm " 888 cm 4 , 932 cm 4 ,
- compositions may additionally include one or more pharmaceutically acceptable excipients, auxiliary materials, carriers, active agents or combinations thereof.
- said Ivacaftor complex used in the present invention has a particle size between 10 nm and 600 nm.
- said Ivacaftor complex used in the present invention has a particle size in the range between 10 nm and 400 nm.
- said Ivacaftor complex used in the present invention is instantaneously redispersible in physiological relevant media.
- said Ivacaftor complex used in the present invention has increased dissolution rate compared to the commercially available form of Ivacaftor, both alone and in combination (KALYDECO® and ORKAMBI®).
- said Ivacaftor complex used in the present invention is stable in solid form and in colloid solution and/ or dispersion.
- said Ivacaftor complex used in the present invention has apparent solubility in water is at least 1 mg/ mL.
- said Ivacaftor complex used in the present invention exhibits X-ray amorphous character in the solid form.
- said Ivacaftor complex used in the present invention has a PAMPA permeability of at least 0.2* 10 "6 cm/s when dispersed in distilled water, which does not decrease in time for at least 6 months.
- the variability of exposure of the Ivacaftor complex used in the present invention is significantly reduced compared to the commercially available form, both alone and in combination (KALYDECO® and ORKAMBI®).
- said Ivacaftor complex used in the present invention has no observable food effect, which allows the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form.
- said Ivacaftor complex used in the present invention containing copolymer of vinylpyrrolidone and vinylacetate and poloxamer and sodium lauryl sulfate, or its pharmaceutical composition characterized by the Raman spectrum shown in Figure 11 and ATR spectrum shown in Figure 12.
- said Ivacaftor complex used in the present invention is characterized by characteristic Raman shifts at 552 cm 1 , 648 cm 1 , 826 cm 4 ,845 cm 1 , 888 cm 1 , 932 cm 1 , 1026 cm 1 , 1062 cm 1 , 1082 cm 1 , 1129 cm 1 , 1140 cm 1 , 1208 cm 1 , 1233 cm 1 , 1262 cm 1 , 1284 cm 1 , 1295 cm 1 , 1361 cm 1 , 1450 cm 1 , 1528 cm 1 , 1573 cm 1 , 1618 cm 1 , 1677 cm 1 , 1738 cm 1 , 746 cm 1 , 2884 cm 4 and 2936 cm 4 .
- said Ivacaftor complex used in the present invention is characterized by characteristic Raman shifts at 1082 cm 1 , 1233 cm 1 , 1284 cm 1 , 1361 cm 4 , 1528 cm 1 , 1618 cm 1 and 1738 cm .
- said Ivacaftor complex used in the present invention is characterized by ATR spectrum having characteristic peaks at 588 cm 4 , 628 cm 4 , 767 cm 4 , 842 cm 4 , 962 cm 4 , 1019 cm 1 , 1108 cm 1 , 1148 cm 1 , 1240 cm , 1343 cm 1 , 1370 cm 1 , 1425 cm , 1465 cm 1 , 1525 cm 1567 cm 1 , 1666 cm and 1732 cm .
- said Ivacaftor complex used in the present invention is characterized by ATR spectrum having characteristic peaks at 628 cm 4 , 767 cm 4 , 1108 cm 4 , 1370 cm 4 , 1465 cm 4 and 1666 cm 4 .
- said Ivacaftor complex used in the present invention comprises a) Ivacaftor; or a combination of active compounds including Ivacaftor; b) a complexing agent which is a copolymer of vinylpyrrolidone and vinylacetate and optionally a poloxamer; and c) sodium lauryl sulfate as a pharmaceutically acceptable excipient.
- said Ivacaftor complex used in the present invention comprises a complexation agent which is a copolymer of vinylpyrrolidone and vinylacetate and optionally a poloxamer which is poloxamer 407 or poloxamer 338 and a pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount comprising from about 1.0 weight% to about 95.0 weight % based on the total weight of the complex.
- said Ivacaftor complex used in the present invention comprises a complexation agent which is a copolymer of vinylpyrrolidone and vinylacetate and optionally a poloxamer which is poloxamer 407 or poloxamer 338 and a pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount comprising from about 50 weight% to about 95 weight% of the total weight of the complex.
- the stable complex of Ivacaftor as used in the present invention comprises a. 5— 40% by weight of Ivacaftor, or a salt or derivative thereof; b. 20— 80% by weight of a copolymer of vinylpyrrolidone and vinylacetate; c. 5— 40 % by weight of sodium lauryl sulfate; and optionally d. 0— 50 % by weight of a poloxamer.
- the manufacturing of the stable complex of Ivacaftor used in the present invention comprises the step of mixing a pharmaceutically acceptable solution containing Ivacaftor and at least one complexing agent and optionally one or more pharmaceutically acceptable excipients with an aqueous solution containing optionally least one pharmaceutically acceptable excipient.
- said Ivacaftor complex used in the present invention is obtained via a mixing process.
- said Ivacaftor complex used in the present invention is obtained via a continuous flow mixing process.
- said process is performed in a continuous flow instrument.
- said continuous flow instrument is a microfluidic flow instrument.
- said Ivacaftor complex used in the present invention is not obtained via a milling process, high pressure homogenization process, encapsulation process and solid dispersion processes.
- the solvent of said pharmaceutically acceptable solution is chosen from water, methanol, ethanol, 1-propanol, 2-propanol, acetone, acetonitrile, dimethyl-sulfoxide, tetrahydrofuran, methyl-ethyl ketone or combinations thereof.
- said pharmaceutically acceptable solvent is tetrahydrofuran.
- said pharmaceutically acceptable solvent and said aqueous solution are miscible with each other.
- said aqueous solution comprises 0.1 to 99.9% weight of the final solution.
- said aqueous solution comprises 50 to 90% weight of the final solution.
- said aqueous solution comprises 50 to 80% weight of the final solution.
- said aqueous solution comprises 50 to 70% weight of the final solution.
- said aqueous solution comprises 50 to 60% weight of the final solution.
- said aqueous solution comprises 45 to 55% weight of the final solution.
- said aqueous solution comprises 50 % weight of the final solution.
- said aqueous solution comprises 35 to 45 % weight of the final solution.
- said aqueous solution comprises 25 to 35 % weight of the final solution. [0092] In an embodiment, said aqueous solution comprises 15 to 25 % weight of the final solution.
- said aqueous solution comprises 5 to 15 % weight of the final solution.
- a pharmaceutical composition comprising the Ivacaftor complex together with pharmaceutically acceptable carrier.
- the complex Lumacaftor formulation used in the present invention comprises Lumacaftor; a complexing agent which is a copolymer of vinylpyrrolidone and vinylacetate and sodium lauryl sulfate as a pharmaceutically acceptable excipient; said complexes characterized in that they possess at least one of the following properties: a) is instantaneously redispersable in physiological relevant media; b) is stable in solid form and in colloid solution and/ or dispersion; c) has apparent solubility in water of at least 1 mg/ mL; d) has a PAMPA permeability of at least 2* 10 ⁇ 6 cm/s when dispersed in FaSSIF or FeSSIF biorelevant media, which does not decrease in time at least for at least 1, preferably 6 month; e) exhibits no observable food effect in-vitro.
- said Lumacaftor complex used in the present invention possesses at least two of the properties described in a)-e) .
- said Lumacaftor complex used in the present invention possesses at least three of the properties described in a)-e) .
- Lumacaftor complex formulations used in the present invention possess instantaneous redispersibility, increased apparent solubility and permeability in fasted and fed state simulation that is expected to deliver full absorption and the elimination of the food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form.
- the expression Lumacaftor is generally used for Lumacaftor, or its salts or its derivatives.
- said complexation agent used in the Lumacaftor complex as used in the present invention is a copolymer of vinylpyrrolidone and vinylacetate.
- said copolymer of vinylpyrrolidone and vinyl acetate has a 60:40 ratio of vinylpyrrolidone:vinyl acetate monomers.
- said pharmaceutically acceptable excipient used in the Lumacaftor complex as used in the present invention is sodium lauryl sulfate.
- said Lumacaftor complex formulation is characterized by a) Raman shifts at 553 cm 4 , 602 cm 1 , 635 cm 4 , 654 cm 4 , 747 cm , 841 cm 4 , 899 cm 4 , 934 cm 4 , 1002 cm , 1021 cm , 1117 cm 4 , 1205 cm , 1232 cm 1 , 1310 cm 4 , 1352 cm , 1372 cm 4 , 1428 cm “ 1444 cm , 1497 cm , 1592 cm 4 , 1609 cm , 1677 cm 1 and 1737 cm 4 ; and b) infrared (ATR) peaks at 635 cm 4 , 703 cm 4 , 747 cm 4 , 837 cm , 1021 cm , 1165 cm 4 , 1231 cm 1288 cm , 1369 cm , 1423 cm 4 , 1462 cm , 1494 cm 4 , 1667 cm 1 and 1731 cm .
- ATR infrared
- the pharmaceutical compositions may additionally include one or more pharmaceutically acceptable excipients, auxiliary materials, carriers, active agents or combinations thereof.
- said Lumacaftor complexes used in the present invention have particle size between 10 nm and 500 nm.
- said particle size is between 10 nm and 250 nm.
- said Lumacaftor complex used in the present invention has increased dissolution rate compared to the commercially available form of Lumacaftor (crystalline form of Lumacaftor).
- said Lumacaftor complex used in the present invention is stable in solid form and in colloid solution and/ or dispersion. [00110] In an embodiment, said Lumacaftor complex used in the present invention has apparent solubility in water is at least 1 mg/ mL. [00111] In an embodiment, said Lumacaftor complex used in the present invention exhibits X-ray amorphous character in the solid form.
- said Lumacaftor complex used in the present invention has a PAMPA permeability of at least 2* 10 ⁇ 6 cm/s when dispersed in distilled water, which does not decrease in time at least for 1, preferably 6 months.
- the variability of exposure of said Lumacaftor complex used in the present invention is significantly reduced compared to the commercially available form (OR AMBI®).
- said Lumacaftor complex used in the present invention has no observable food effect in-vitro, which allows the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form.
- said Lumacaftor complex used in the present invention is characterized by Raman shifts at 553 cm 4 , 602 cm 4 ,635 cm 4 , 654 cm 4 , 747 cm 4 , 841 cm 4 , 899 cm 4 , 934 cm , 1002 cm , 1021 cm 4 , 1117 cm , 1205 cm , 1232 cm , 1310 cm , 1352 cm , 1372 cm 4 , 1428 cm 4 , 1444 cm 4 , 1497 cm 4 , 1592 cm 1 , 1609 cm 4 , 1677 cm 1 and 1737 cm .
- said Lumacaftor complex used in the present invention is characterized by infrared (ATR) peaks at 635 cm 4 , 703 cm 4 , 747 cm 4 , 837 cm 4 , 1021 cm 4 , 1165 cm 4 , 1231 cm 4 , 1288 cm 4 , 1369 cm 4 , 1423 cm 1 , 1462 cm 1 , 1494 cm 1 , 1667 cm 1 and 1731 cm 1 .
- ATR infrared
- said Lumacaftor complex used in the present invention comprises a) Lumacaftor; or a combination of active compounds including Lumacaftor; b) a complexing agent which is a copolymer of vinylpyrrolidone and vinylacetate; and c) sodium lauryl sulfate as an excipient.
- said complex Lumacaftor formulation used in the present invention comprises complexation agent which is a copolymer of vinylpyrrolidone and vinylacetate and a pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount ranging from about 1.0 weight % to about 95.0 weight % based on the total weight of the complex.
- said Lumacaftor complex used in the present invention comprises complexation agent which is copolymer of vinylpyrrolidone and vinylacetate and pharmaceutically acceptable excipient which is sodium lauryl sulfate comprise 50 weight % to about 95 weight % of the total weight of the complex.
- the stable complex of Lumacaftor as used in the present invention comprises a. 5— 40% by weight of Lumacaftor, its salt, or derivatives thereof; b. 50— 90% by weight of copolymer of vinylpyrrolidone and vinylacetate; c. 0.01— 40 % by weight of sodium lauryl sulfate
- the manufacturing of the stable complex of Lumacaftor used in the present invention comprises the step of mixing a pharmaceutically acceptable solution containing Lumacaftor and at least one complexing agent and optionally one or more pharmaceutically acceptable excipient with an aqueous solution containing optionally at least one pharmaceutically acceptable excipient.
- said Lumacaftor complex used in the present invention is obtained via a mixing process.
- said Lumacaftor complex used in the present invention is obtained via a continuous flow mixing process.
- said process is performed in a continuous flow instrument.
- said continuous flow instrument is a microfluidic flow instrument.
- said Lumacaftor complex used in the present invention is not obtained via a milling process, high pressure homogenization process, encapsulation process and solid dispersion processes.
- the solvent of said pharmaceutically acceptable solution is chosen from methanol, ethanol, 1-propanol, 2-propanol, acetone, acetonitrile, dimethyl-sulfoxide, tetrahydrofuran, methyl-ethyl ketone or combinations thereof.
- said pharmaceutically acceptable solvent is methanol.
- said pharmaceutically acceptable solvent and said aqueous solution are miscible with each other.
- said aqueous solution comprises 0.1 to 99.9% weight of the final solution. [00132] In an embodiment, said aqueous solution comprises 50 to 90% weight of the final solution.
- said aqueous solution comprises 50 to 80% weight of the final solution.
- said aqueous solution comprises 50 to 70% weight of the final solution.
- said aqueous solution comprises 50 to 60% weight of the final solution.
- said aqueous solution comprises 45 to 55% weight of the final solution. [00137] In an embodiment, said aqueous solution comprises 50 % weight of the final solution.
- said aqueous solution comprises 35 to 45 % weight of the final solution.
- said aqueous solution comprises 25 to 35 % weight of the final solution. [00140] In an embodiment, said aqueous solution comprises 15 to 25 % weight of the final solution.
- said aqueous solution comprises 5 to 15 % weight of the final solution.
- a pharmaceutical composition comprising the complex together with pharmaceutically acceptable carriers.
- the complexing agents themselves or together with the pharmaceutically acceptable excipients have the function to form a complex structure with an active pharmaceutical ingredient through non-covalent secondary interactions.
- the secondary interactions can form through electrostatic interactions such as ionic interactions, H-bonding, dipole-dipole interactions, dipole-induced dipole interactions, London dispersion forces, ⁇ - ⁇ interactions, and hydrophobic interactions.
- the complexing agents, pharmaceutically accepted excipients and active ingredients are selected from the group of complexing agents, pharmaceutically accepted excipients and active ingredients which are able to form such complex structures through non-covalent secondary interactions.
- the pharmaceutical combination composition used in the present invention comprises a) Complex Ivacaftor formulation comprising Ivacaftor, a complexing agent which is a copolymer of vinylpyrrolidone and vinylacetate and optionally a poloxamer and sodium lauryl sulfate as a pharmaceutically acceptable excipient; and b) Complex Lumacaftor formulation comprising Lumacaftor, a complexing agent which is a copolymer of vinylpyrrolidone and vinylacetate and sodium lauryl sulfate as a pharmaceutically acceptable excipient; and c) optionally, additional pharmaceutically acceptable excipients wherein said pharmaceutical combination composition characterized in that they possess at least one of the following properties: a) is instantaneously redispersable in physiological relevant media; b) is stable in solid form and in colloid solution and/ or dispersion; c) apparent solubility both for Ivacaftor and Lumacaftor in water is at least 1 mg/
- said pharmaceutical combination composition used in the present invention possesses at least three of the properties described in a)-e).
- the pharmaceutical combination composition used in the present invention possesses instantaneous redispersibility, increased apparent solubility and permeability in fasted and fed state simulation that is expected to deliver full absorption and the elimination of the food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted pharmaceutical combination composition in solution form.
- said pharmaceutical combination composition may additionally include one or more pharmaceutically acceptable excipients, auxiliary materials, carriers, active agents or combinations thereof.
- said pharmaceutical combination composition used in the present invention has increased dissolution rate compared to the commercially available form (ORKAMBI®).
- said pharmaceutical combination composition used in the present invention is stable in solid form and in colloid solution and/ or dispersion.
- said pharmaceutical combination composition used in the present invention has PAMPA permeability both for Ivacaftor and Lumacaftor complex formulations is at least 0.2* 10 "6 cm/s for Ivacaftor and 2* 10 ⁇ 6 cm/s for Lumacaftor when dispersed in water or biorelevant media, which does not decrease in time at least for 6 months.
- the variability of exposure of said pharmaceutical combination composition used in the present invention is significantly reduced compared to the commercially available form (ORKAMBI®).
- said pharmaceutical combination composition used in the present invention has no observable food effect in-vitro, which allows the opportunity of precise dosing and ease of administration of the reconstituted pharmaceutical combination composition in solution form.
- said pharmaceutical combination composition used in the present invention comprises complexation agent which is a copolymer of vinylpyrrolidone and vinylacetate and optionally a poloxamer and a pharmaceutically acceptable excipient which is sodium lauryl sulfate, in a total amount ranging from about 1.0 weight % to about 95.0 weight % based on the total weight of the pharmaceutical combination composition.
- said pharmaceutical combination composition used in the present invention comprises complexation agent which is a copolymer of vinylpyrrolidone and vinylacetate and optionally a poloxamer and a pharmaceutically acceptable excipient which is sodium lauryl sulfate comprise 50 weight % to about 95 weight % of the total weight of the pharmaceutical combination composition.
- said pharmaceutical combination composition comprises of 50 to 300 mg Ivacaftor equivalent complex Ivacaftor formulation in combination with 25 to 250 mg Lumacaftor equivalent complex Lumacaftor formulation.
- the manufacturing of the pharmaceutical combination composition used in the present invention includes the step of mixing a pharmaceutically acceptable solution containing Ivacaftor and at least one complexing agent and optionally one or more pharmaceutically acceptable excipients with an aqueous solution containing optionally at least one pharmaceutically acceptable excipient and solidification of the resulted solution mixture; and the step of mixing a pharmaceutically acceptable solution containing Lumacaftor and at least one complexing agent and optionally one or more pharmaceutically acceptable excipients with an aqueous solution containing optionally at least one pharmaceutically acceptable excipient and solidification of the resulted solution mixture; and the step of blending and granulation of the solidified Ivacaftor and Lumacaftor complex formulations.
- the manufacturing of the pharmaceutical combination composition used in the present invention comprises the step of mixing a pharmaceutically acceptable solution containing Ivacaftor and Lumacaftor and at least one complexing agent and optionally one or more pharmaceutically acceptable excipients with an aqueous solution containing optionally at least one pharmaceutically acceptable excipient.
- said Ivacaftor complex used in the present invention is obtained via a mixing process.
- said Lumacaftor complex used in the present invention is obtained via a mixing process.
- said complex of Ivacaftor and Lumacaftor used in the present invention is obtained via a mixing process.
- said mixing process is a continuous flow mixing process.
- said process is performed in a continuous flow instrument.
- said continuous flow instrument is a microfluidic flow instrument.
- the solvent of said pharmaceutically acceptable solution is chosen from methanol, ethanol, 1-propanol, 2-propanol, acetone, acetonitrile, dimethyl-sulfoxide, tetrahydrofuran, methyl-ethyl ketone or combinations thereof.
- said pharmaceutically acceptable solvent is a solvent mixture of methanol and tetrahydrofurane.
- said pharmaceutically acceptable solvent and said aqueous solution are miscible with each other.
- said aqueous solution comprises 0.1 to 99.9% weight of the final solution.
- said aqueous solution comprises 50 to 90% weight of the final solution.
- said aqueous solution comprises 50 to 80% weight of the final solution.
- said aqueous solution comprises 50 to 70% weight of the final solution.
- said aqueous solution comprises 50 to 60% weight of the final solution.
- said aqueous solution comprises 45 to 55% weight of the final solution. [00175] In an embodiment, said aqueous solution comprises 50 % weight of the final solution.
- said aqueous solution comprises 35 to 45 % weight of the final solution.
- said aqueous solution comprises 25 to 35 % weight of the final solution.
- said aqueous solution comprises 15 to 25 % weight of the final solution.
- said aqueous solution comprises 5 to 15 % weight of the final solution.
- a pharmaceutical composition comprising the complex together with pharmaceutically acceptable carriers.
- the pharmaceutical combination composition of the invention comprising complex Ivacaftor and complex Lumacaftor formulations can be formulated: (a) for administration selected from the group consisting of oral, pulmonary, rectal, colonic, parenteral, intracisternal, intravaginal, intraperitoneal, ocular, otic, local, buccal, nasal, and topical administration; (b) into a dosage form selected from the group consisting of liquid dispersions, gels, aerosols, ointments, creams, lyophilized formulations, tablets, capsules; (c) into a dosage form selected from the group consisting of controlled release formulations, fast melt formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release formulations; or (d) any combination of (a), (b), and (c).
- the pharmaceutical combination compositions can be formulated by adding different types of pharmaceutically acceptable excipients for oral administration in solid, liquid, local (powders, ointments or drops), or topical administration, and the like.
- the dosage form of the invention is a solid dosage form, although any pharmaceutically acceptable dosage form can be utilized.
- Solid dosage forms for oral administration include, but are not limited to, capsules, tablets, pills, powders (sachet), and granules.
- the complex formulations of the present invention is admixed with at least one of the following: one or more inert excipients (or carriers): (a) fillers or extenders, such as, lactose, sucrose, glucose, mannitol, sorbitol, dextrose, dextrates, dextrin, erythritol, fructose, isomalt, lactitol, maltitol, maltose, maltodextrin, trehalose, xylitol, starches, microcrystalline cellulose, dicalcium phosphate, calcium carbonate, magnesium carbonate, magnesium oxide; (b) sweetening, flavoring, aromatizing and perfuming agents such as saccharin, saccharin sodium, acesulfame potassium, alitame,
- the dosage form of the invention is a liquid dispersible granules in a sachet form.
- said liquid dispersible granules comprise said complex Ivacaftor formulation and said complex Lumacaftor formulation and optionally pharmaceutically acceptable excipients.
- said pharmaceutically acceptable excipients selected from the group of fillers or extenders, such as, lactose, sucrose, glucose, mannitol, sorbitol, dextrose, dextrates, dextrin, erythritol, fructose, isomalt, lactitol, maltitol, maltose, maltodextrin, trehalose, xylitol, starches, microcrystalline cellulose, dicalcium phosphate, calcium carbonate, magnesium carbonate, magnesium oxide.
- fillers or extenders such as, lactose, sucrose, glucose, mannitol, sorbitol, dextrose, dextrates, dextrin, erythritol, fructose, isomalt, lactitol, maltitol, maltose, maltodextrin, trehalose, xylitol, starches, microcrystalline cellulose, dicalcium phosphate
- pharmaceutically acceptable excipients selected from the group of sweetening, flavoring, aromatizing and perfuming agents such as saccharin, saccharin sodium, acesulfame potassium, alitame, aspartame, glycine, inulin, neohesperidin dihydrochalcone, neotame, sodium cyclamate, sucralose, tagatose, thaumatin, citric acid, adipic acid, fumaric acid, leucine, malic acid, menthol, propionic acid, tartaric acid.
- a liquid dispersible granules comprising a. 25 —95 % pharmaceutical combination composition comprising complex Ivacaftor and complex Lumacaftor formulations;
- liquid dispersible granules disperses within 3 min in liquid; and wherein said liquid dispersible granules obtained by wet or dry processes.
- said dispersion time is between 0.1 min and 10 min.
- said dispersion time is between 0.1 min and 5 min.
- said dispersion time is between 0.1 min and 3 min.
- said dispersion time is between 0.1 min and 1 min.
- Hausner-ratio of the said liquid dispersible granules is less than 1.25 more preferably 1.00-1.18
- Hausner-ratio of the said liquid dispersible granules is between 1.00 and 1.18.
- the particle size (D(90)) of said liquid dispersible granules is less than 2000 micrometers.
- 60-99 % of the said liquid dispersible granules are in the size range of 160-1200 micrometers.
- said liquid is water, saliva, other physiologically or biologically acceptable fluid.
- compositions of the invention include, but are not limited to (1) physical and chemical stability, (2) instantaneous redispersibility, (3) stability in colloid solution or dispersion in the therapeutic time window, (4) increased apparent solubility and permeability compared to the conventional formulations, (5) no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex formulation in solution form, (6) good processability.
- the pharmaceutical combination composition of the present invention has increased apparent solubility and permeability.
- the apparent solubility and permeability of the pharmaceutical combination composition is at least 1 mg/ mL and 0.2* 10 "6 cm/s.
- the pharmaceutical combination composition of the present invention possess instantaneous redispersibility, increased apparent solubility and permeability, no observable food effect which deliver the opportunity of precise dosing and ease of administration of the redispersed solid.
- Figure 1 shows physical appearance and stability of the produced complex Ivacaftor formula during the flow optimization.
- Figure 2. shows apparent solubility of complex Ivacaftor and Lumacaftor formulations alone and in combinations.
- Figure 3. shows GI tract simulated dissolution of Ivacaftor and Lumacaftor from the
- Figure 4. shows Ivacaftor and Lumacaftor dissolution from the pharmaceutical combination composition prepared by spray drying in combination and powder blending.
- Figure 5. shows PAMPA permeabilities of complex Ivacaftor formulation and complex
- Figure 6 shows PAMPA permeabilities of complex Ivacaftor formulation and complex
- Lumacaftor formulation in the pharmaceutical combination composition prepared by powder blending is prepared by powder blending.
- Figure 7 shows PAMPA permeabilities of complex Ivacaftor formulation and complex
- Lumacaftor formulation in the pharmaceutical combination composition prepared by spray- drying in combination prepared by spray- drying in combination.
- Figure 8 shows PAMPA permeability of complex Ivacaftor and complex Lumacaftor formulations stored at different conditions.
- Figure 9 shows PAMPA permeability of complex Ivacaftor and complex Lumacaftor formulations in the pharmaceutical composition stored at different conditions.
- Figure 10 shows SEM photos of complex Ivacaftor (A) and complex Lumacaftor (B) formulations.
- Figure 11 shows Raman spectra of crystalline Ivacaftor (A), freeze-dried Ivacaftor (B), Complex Ivacaftor formulation (C), Placebo sample (prepared in the absence of Ivacaftor) (D), Luviskol VA64 (E), sodium lauryl sulfate (F) and poloxamer (Poloxamer 338 - Pluronic F108) Pluronic F108 (G).
- Figure 12 shows ATR spectra of crystalline Ivacaftor (A), amorphous Ivacaftor (B), complex Ivacaftor formulation (C), placebo (prepared in the lack of Ivacaftor) (D), Luviscol VA64 (E), sodium lauryl sulfate (F) and poloxamer (Poloxamer 338 - Pluronic F108) (G).
- Figure 13 shows Raman spectra of crystalline Lumacaftor (A), amorphous Lumacaftor (B), complex Lumacaftor formulation (C), placebo (D), Luviscol VA64 (E), SDS (F)
- Figure 14 shows ATR spectra of crystalline Lumacaftor (A), amorphous Lumacaftor (B), complex Lumacaftor formulation (C), placebo (D), Luviscol VA64 (E), SDS (F).
- Figure 15. shows XRD diffractograms of crystalline Ivacaftor (A, C), complex Ivacaftor formulation (A), crytalline Lumacaftor (B, C) and complex Lumacaftor formulation (B) and Spray-dried complex Ivacaftor and complex Lumacaftor formulations in combination (C)
- Figure 16. shows PAMPA permeability of crystalline Ivacaftor, solid dispersion of Ivacaftor and complex Ivacaftor formulation.
- Figure 17. shows comparative apparent solubility data of different Ivacaftor formulations.
- Figure 18 shows comparative dissolution tests of solid dispersion of Ivacaftor and complex Ivacaftor formulation.
- Figure 19 shows particle size of different of Ivacaftor and Lumacaftor formulation.
- FIG. 20 shows apparent solubility of Lumacaftor formulations.
- Figure 21 shows comparative PAMPA permeability of Lumacaftor formulations.
- Figure 22 shows dissolution of Ivacaftor from different pharmaceutical formulations.
- Figure 23 shows dissolution of Lumacaftor from different pharmaceutical formulations.
- Figure 24 shows comparative PAMPA permeability of different, ORKAMBI® equivalent Ivacaftor and Lumacaftor formulations.
- a solution mixture of complex Ivacaftor formulation of the present invention was prepared by mixing process.
- Solution 1 containing 500 mg Ivacaftor and 1500 mg vinylpyrrolidone and vinylacetate copolymer (Luviskol VA 64) and 1000 mg poloxamer (Poloxamer 338— Pluronic F108) in 100 mL tetrahydrofuran was mixed with aqueous Solution 2 containing 500 mg sodium lauryl sulfate in 100 mL ultrapurified water in different flow rates.
- 1 :1 Solvent 1 : Solvent 2 ratio was used.
- the colloid solution of the complex Ivacaftor formulation was produced at atmospheric pressure and 20-50 °C temperature. The appearance and stability of the produced colloid solution were monitored. Based on the physical appearance and stability of the produced complex Ivacaftor formulation in colloid solution, the best composition was selected for spray-drying experiments.
- Figure 1 summarizes the results.
- the solidification of the colloid solution was performed by spray-drying technique. 5 mg/ mL Ivacaftor, 15 mg/ mL vinylpyrrolidone and vinylacetate copolymer (Luviskol VA 64) and 10 mg/mL poloxamer (Poloxamer 338 — Pluronic F108) in tetrahydrofurane and 5mg/mL sodium lauryl sulfate in water were chosen for starting concentrations. The ratio of the solutions was found to be optimal at 1:1 ratio. The colloid solution of the complex Ivacaftor formulation prepared by the optimal parameter sets was spray-dried (Yamato DL-410 / GAS410) in order to obtain solid powder.
- a solution mixture of Lumacaftor complex formulation was prepared by continuous flow mixing approach. 20 mL Solution 1 was prepared by dissolving 40 mg Lumacaftor and 180 mg copolymer of vinylpyrrolidone and vinylacetate in 20 mL methanol. The prepared Solution 1 was mixed with Solution 2 containing 24 mg sodium lauryl sulfate in 80 mL water at 1:4 volume ratio in order to produce complex Lumacaftor formulation. The solution mixture of the complex Lumacaftor formulation was produced at atmospheric pressure and ambient temperature. The produced solution mixture was frozen on dry-ice and then it was lyophilized using a freeze drier equipped with -110°C ice condenser, with a vacuum pump. Spray-drying was also applicable to produce solid powder from the solution mixture of complex Lumacaftor formulation. Manufacturing of pharmaceutical combination composition
- composition of the present invention was prepared by blending the powders of complex Ivacaftor and Lumacaftor formulations.
- the resulted pharmaceutical composition contained the complex Ivacaftor and complex Lumacaftor formulation in 125:200 active compound equivalent ratio.
- a solution mixture of pharmaceutical combination composition of the present invention was prepared by mixing process.
- Solution 1 containing 192 mg Ivacaftor and 308 mg Lumacaftor and 1000 mg vinylpyrrolidone and vinylacetate copolymer (Luviskol VA 64) in 100 mL solvent mixture of methanol and tetrahydrofuran having volume ratio of 5:2 was mixed with aqueous Solution 2 containing 150 mg sodium lauryl sulfate in 400 mL ultrapurified water in different flow rates.
- Solvent 1 : Solvent 2 ratio was 1 :4.
- the colloid solution of the complex Ivacaftor formulation was produced at atmospheric pressure and 25 °C temperature. The solidification of the colloid solution was performed by spray-drying technique.
- Liquid dispersible granules of complex Ivacaftor formulations of the present invention can be obtained by wet or dry granulation processes.
- Dry granulation process includes, but not limited to the slugging or roll compaction of the powder formulation of complex Ivacaftor into compacts and breaking of the compacts into granules with appropriate mesh size.
- the obtained granules can be mixed with pharmaceutically acceptable excipients.
- Dry granulation technique can be also applied on the powder blend of complex Ivacaftor formulations.
- Powder blend consists of the powder formulation of complex Ivacaftor and pharmaceutically acceptable excipients and prepared by mixing of powders. Slugging or roll compaction are used to manufacture compacts from the powder blend. Then the compacts are broken into granules with appropriate mesh size.
- Wet granulation process covers the moisturizing of the powder formulations of complex Ivacaftor (direct granulation) or moisturizing the pharmaceutically acceptable excipients with aqueous solution of pharmaceutically acceptable binders and mixing it with the powder formulations of complex Ivacaftor (indirect granulation).
- the particle size of the granules can be controlled by physical impact before and after the drying step.
- Liquid dispersible granules of complex Ivacaftor formulation of the present invention were prepared by compacting appropriate amount of complex Ivacaftor powder blend using 0.5 ton load.
- the powder blend comprised of the solid formulation of the complex of Ivacaftor and pharmaceutically acceptable excipients selected from the group of sweetening, flavouring, aromatizing and perfuming agents.
- the height of the compact was found to be optimal between 0.8-1.0 mm.
- the compacts were broken up by physical impact to form granulates.
- the particle size of the granules was controlled by sieving with appropriate mesh size to achieve 160-800 micrometres particle size.
- Liquid dispersible granules of complex Lumacaftor formulations of the present invention can be obtained by wet or dry granulation processes.
- Dry granulation process includes, but not limited to the slugging or roll compaction of the powder formulation of complex Lumacaftor into compacts and breaking of the compacts into granules with appropriate mesh size.
- the obtained granules can be mixed with pharmaceutically acceptable excipients.
- Powder blend consists of the powder formulation of complex Lumacaftor and pharmaceutically acceptable excipients and prepared by mixing of powders. Slugging or roll compaction are used to manufacture compacts from the powder blend. Then the compacts are broken into granules with appropriate mesh size.
- Wet granulation process covers the moisturizing of the powder formulations of complex Lumacaftor (direct granulation) or moisturizing the pharmaceutically acceptable excipients with aqueous solution of pharmaceutically acceptable binders and mixing it with the powder formulations of complex Lumacaftor (indirect granulation).
- the particle size of the granules can be controlled by physical impact before and after the drying step.
- Liquid dispersible granules of complex Lumacaftor formulation of the present invention were prepared by compacting appropriate amount of complex Lumacaftor powder blend using 0.5 ton load.
- the powder blend comprised of the solid formulation of the complex of Lumacaftor and pharmaceutically acceptable excipients selected from the group of sweetening, flavouring, aromatizing and perfuming agents.
- the height of the compact was found to be optimal between 0.8-1.0 mm.
- the compacts were broken up by physical impact to form granulates.
- the particle size of the granules was controlled by sieving with appropriate mesh size to achieve 160-800 micrometres particle size.
- Liquid dispersible granules of pharmaceutical combination composition of the present invention can be obtained by blending the liquid dispersible granule or pellets of complex Ivacaftor formulation and complex Lumacaftor formulation; or mixing the complex Ivacaftor formulation with the complex Lumacaftor formulation before granulation, pelletising; or blending the liquid dispersible granules or pellets of the complex Ivacaftor formulation or complex Lumacaftor formulation with the solid form of the complex Ivacaftor formulation or complex Lumacaftor formulation.
- Liquid dispersible granules of pharmaceutical combination composition of the present invention can be obtained by compacting appropriate amount of pharmaceutical combination composition prepared by spray-drying in combination using 0.5-3 ton load.
- the powder comprised of the solid formulation of the pharmaceutical combination composition and pharmaceutically acceptable excipients selected from the group of sweetening, flavouring, aromatizing and perfuming agents.
- the height of the compact was found to be optimal between 0.8-1.0 mm.
- the compacts were broken up by physical impact to form granulates.
- the particle size of the granules was controlled by sieving with appropriate mesh size to achieve 160-800 micrometres particle size.
- Blending and mixing include but not limited to container rotating or high shear mixing. Comparative solubility tests
- the apparent solubility was measured by UV-VIS spectroscopy or RP-HPLC at room temperature.
- the samples were dispersed in ultrapurified water in 1-20 mg/mL active ingredient equivalent concentration range.
- the resulting solutions were filtered by 100 nm disposable syringe filter.
- the active ingredient content in the filtrate was measured by UV-Vis spectrophotometry or RP-HPLC and the apparent solubility was calculated.
- the filtrate may contain particles which could not be filtrated out using 100 nm pore size filter.
- Figure 2 shows the results.
- he apparent solubility of complex Ivacaftor formulation of the present invention was 0.991; 2.356; 4.924; 9.463 mg/mL and 18.474, when 1; 2.5; 5; 10 and 20 mg/mL Ivacator equivalent formulations were dispersed in ultrapurified water, respectively.
- Apparent solubility of complex Ivacaftor formulation was 18.474 mg/mL.
- he apparent solubility of complex Lumacaftor formulation of the present invention was 0.950; 9.839 and 14.913 mg/mL, when 1; 10 and 20 mg/mL Lumacaftor equivalent formulations were dispersed in ultrapurified water, respectively.
- the apparent solubility of unformulated crystalline Lumacaftor was found to be 0.032 mg/mL.
- Solubility of complex Lumacaftor formula was 14.913 mg/mL.
- the apparent solubility of pharmaceutical combination composition of the present invention prepared by powder blending was 1.009; 4.6967; 9.591 mg/mL and 19.9493 mg/mL for Lumacaftor and 0.6117; 2.8444; 5.7553 mg/mL and 11.3187 mg/mL for Ivacaftor, when 1; 5; 10 and 20 mg/mL Lumacaftor equivalent formulations were dispersed in ultrapurified water, respectively.
- Apparent solubility of pharmaceutical combination composition of the present invention prepared by powder blending was 19.9493 mg/mL for Lumacaftor and 11.3187 mg/mL for Ivacaftor.
- the apparent solubility of pharmaceutical combination composition of the present invention prepared by spray drying in combination was 0.9656; 4.8253; 8.9099 mg/mL and 19.2660 mg/mL for Lumacaftor and 0.5969; 3.0105; 5.5397 mg/mL and 12.0467 mg/mL for Ivacaftor, when 1; 5; 10 and 20 mg/mL Lumacaftor equivalent formulations were dispersed in ultrapurified water, respectively.
- Apparent solubility of pharmaceutical combination composition of the present invention prepared by spray drying was 19.2660 mg/mL for Lumacaftor and 12.0467 mg/mL for Ivacaftor. Dissolution test
- Gastro-intestinal tract simulated drug dissolution tests were performed by dispersing the blended pharmaceutical combination composition described above in purified water.
- the dispersion contained 1 mg/mL Lumacaftor and 0.625mg/mL Ivacaftor (identical mixture to ORKAMBI®).
- simulated gastric fluid SGF V2
- FeSSIF buffer was added to dispersion in order to set-up the pH to 1.6 (fasted state simulation) or FeSSIF buffer to increase the pH to 5.8 (fed state simulation).
- FaSSIF solution was also added to the dispersion to ensure the fasted condition in the intestine simulation. In case of fed state simulation FeSSIF solution was added to the dispersion.
- Drug dissolution tests were performed by dispersing the pharmaceutical combination composition prepared by powder blending or spray-drying in combination in water.
- the dissolved amount of Lumacaftor and Ivacaftor was measured by RP-HPLC after filtration with 0.1 ⁇ pore size filter at different time points.
- Dissolution of Ivacaftor and Lumacaftor prepared by spray drying in combination was instantaneous, within 5 minutes more than 85 % of the Ivacaftor and Lumacaftor dissolved from the pharmaceutical composition of present invention in water. ( Figure 4).
- PAMPA permeability of the complex formulations was measured and compared to the unformulated crystalline reference active compounds. PAMPA permeability measurements were performed as described by M. Kansi et al. Qournal of medicinal chemistry, 41, (1998) pp 1007) with modifications based on S. Bendels et al (Pharmaceutical research, 23 (2006) pp 2525). Permeability was measured in a 96-well plate assay across an artificial membrane composed of dodecane with 20% soy lecithin supported by a PVDF membrane (Millipore, USA). The receiver compartment was phosphate buffered saline (pH 7.0) supplemented with 1% sodium dodecyl sulfate.
- the assay was performed at room temperature; incubation time was 4 hours in ultrapurified water, FaSSIF and FeSSIF, respectively.
- the concentration in the receiver compartment was determined by UV-VIS spectrophotometry or RP-HPLC method (Thermo Scientific multiscan GO spectrophotometer or Thermo Surveyor HPLC or Rigol L-3000 series HPLC).
- PAMPA permeabilities of complex Ivacaftor formulation and complex Lumacaftor formulation were measured in FaSSIF and FeSSIF media and were found to be above 0.5* 10 "6 cm/ s for Ivacaftor and 2* 10 ⁇ 6 cm/ s for Lumacaftor measured by UV-VIS ( Figure 5).
- PAMPA permeabilities of pharmaceutical combination composition prepared by powder blending was measured in water; FaSSIF and FeSSIF media and were found to be above 0.5* 10 "6 cm/ s for Ivacaftor and 2* 10 ⁇ 6 cm/ s for Lumacaftor measured by UV-VIS ( Figure 6).
- PAMPA permeabilities of pharmaceutical combination composition prepared by spray- drying in combination was measured in water; FaSSIF and FeSSIF media and were found to be above 0.2* 10 ⁇ 6 cm/s for Ivacaftor and 1.5* 10 6 cm/s for Lumacaftor measured by HPLC ( Figure 7) ⁇
- Complex Ivacaftor formulation comprises spherical particles with particle size less than 50 nm, while spherical particles of complex Lumacaftor formulation have particle size in the range of less than 100 nm ( Figure 10).
- Complex Ivacaftor formulation used in the present invention is characterized by Raman shifts at 1082 cm 1 , 1233 cm 1 , 1284 cm 1 , 1361 cm 1 , 1528 cm 1 , 1618 cm 4 and 1738 cm 1 .
- Complex Ivacaftor formulation used in the present invention is characterized by infrared (ATR) spectrum having characteristic peaks at 588 cm 4 , 628 cm 4 , 767 cm 4 , 842 cm 4 , 962 cm 4 , 1019 cm 1 , 1108 cm 1 , 1148 cm 1 , 1240 cm , 1343 cm 1 , 1370 cm 1 , 1425 cm , 1465 cm 1 , 1525 cm 1567 cm 1 , 1666 cm 4 and 1732 cm 4 .
- ATR infrared
- Complex Ivacaftor formulation used in the present invention is characterized by ATR spectrum having characteristic peaks at 628 cm 4 , 767 cm 4 , 1108 cm 4 , 1370 cm 4 , 1465 cm 4 and 1666 cm 4 .
- Complex Lumacaftor formulation used in the present invention is characterized by characteristic Raman shifts at 553 cm 4 , 602 cm 4 , 635 cm 4 , 654 cm 4 , 747 cm 4 , 841 cm 4 , 899 cm 4 , 934 cm 4 , 1002 cm 4 , 1021 cm 4 , 1117 cm 4 , 1205 cm 4 , 1232 cm 4 , 1310 cm 4 , 1352 cm 4 , 1372 cm 4 , 1428 cm 4 , 1444 cm 4 , 1497 cm 4 , 1592 cm 4 , 1609 cm 4 and 1677 cm 4 shown in Figure 13.
- Complex Lumacaftor formulation used in the present invention is characterized by characteristic Raman shifts at 553 cm 4 , 654 cm 4 , 747 cm 4 , 841 cm 4 , 899 cm 4 , 1117 cm 4 , 1205 cm 4 , 1310 cm 4 , 1372 cm 4 , 1428 cm 4 , 1677 cm 4 and 1737 cm 4 .
- Complex Lumacaftor formulation used in the present invention is characterized by characteristic infrared (ATR) peaks at 635 cm 4 , 703 cm 4 , 747 cm 4 , 837 cm 4 , 1021 cm 4 , 1165 cm 4 , 1231 cm 4 , 1288 cm 4 , 1369 cm 4 , 1423 cm 4 , 1462 cm 4 , 1494 cm 4 , 1667 cm 4 and 1731 cm 4 shown in Figure 14.
- ATR characteristic infrared
- Complex Lumacaftor formulation used in the present invention is characterized by characteristic infrared (ATR) peaks at 703 cm 4 , 837 cm 4 , 1231 cm 4 , 1369 cm 4 and 1667 cm 4 .
- ATR characteristic infrared
- the structure of the complex Ivacaftor, complex Lumacaftor formulation and the pharmaceutical combination compositions were investigated by powder X-ray diffraction (XRD) analysis (Philips PW1050/1870 RTG powder-diffractometer). The measurements showed that both the Ivacaftor and Lumacaftor in the complex and in the combination formulations were XRD amorphous ( Figure 15). Characteristic reflections on the diffractograms at 43 and 44 2Theta could be attributed to sample holder.
- Ivacaftor is marketed in its solid dispersion form under the trade name of KALYDECO®. Manufacturing of solid dispersion of Ivacaftor is described in US 20140221424 Al patent application. Using the manufacturing method described in the patent application, solid dispersion of Ivacaftor was prepared for comparative analytical assays. A solvent system of methyl ethyl ketone (MEK) and water in the ratio of 90 wt % MEK : 10 wt % water was heated to 20-30° C in a reaction vessel equipped with a magnetic stirrer and thermal circuit.
- MEK methyl ethyl ketone
- hypromellose acetate succinate polymer HPMCAS
- sodium-lauryl-sulfate sodium-lauryl-sulfate
- Ivacaftor Into this solvent system, hypromellose acetate succinate polymer (HPMCAS), sodium-lauryl-sulfate and Ivacaftor were added in the ratio of 19.5 wt % hypromellose acetate succinate : 0.5 wt % SLS:80 wt % Ivacaftor.
- the resulting mixture was solid formulated by spray-drying method.
- the vessel was washed out with 5 mL Milli-Q water.
- the products were frozen on salted ice and then it was lyophilized using a freeze-drier equipped with -110°C ice condenser, with a vacuum pump.
- the material and in-vitro properties of the resulted formulations were compared to the complex Lumacaftor and Ivacaftor formulations of the present invention.
- Particle size of the formulations was measured by DLS technique in reconstituted dispersion/solution. The results are summarized in Figure 19. Ball milled crystalline Lumacaftor was hardly redispersible in purified water resulting in a suspension with visible particles, the particle size could not be determined.
- PAMPA permeability of the formulations was measured in FaSSIF biorelevant media and compared.
- PAMPA permeability of the complex Lumacaftor formulation was 4.651, while it was 0.288 for the ball milled crystalline Lumacaftor ( Figure 21) .
- GI simulated dissolution of the powder mixture of complex Ivacaftor and Lumacaftor formulations shows completely eliminated food effect both for Ivacaftor and Lumacaftor in in- vitro. Based the dissolution data, significantly increased or full absorption is expected in in-vitro studies. Dissolution of Ivacaftor and Lumacaftor from the powder blend was above 80 % within 5 minutes ( Figure 22 and Figure 23) .
- dissolution of Ivacaftor from the solid dispersion of Ivacaftor showed 5- fold increase in FessiF condition indicating significant difference in its absorption in fed state in- vivo.
- the increase in the dissolution was 3-fold and 1.5 fold for the ball milled solid dispersion of Ivacaftor and ball milled Ivacaftor with Luviskol VA 64 Pluronic F108 and SDS, respectively.
- Dissolution of Lumacaftor from the crystalline material was below 10 % both in FaSSIF and FeSSIF media.
- the dissolution of Lumacaftor increased when the particle size was decreased, however it did not exceed 40 % in any of the tested condition. 2-fold difference in the dissolution was observed in FeSSIF medium compared to the FaSSIF condition ( Figure 22 and Figure 23).
- PAMPA permeability of different compositions were measured and compared.
- PAMPA permeability of complex Ivacaftor and complex Lumacaftor formulation in the pharmaceutical composition of the present invention outperformed the in-vitro performance of the tested formulations ( Figure 24) .
- a beagle dog study using the granulated complex Ivacaftor formulation of the present invention at a dose of 3 mg/kg was performed in the fasted and fed state.
- the granulated complex formulation was administered to the animals orally as reconstituted dispersion.
- Food effect was only 1.1 -fold (food effect in humans is 2-4-fold higher in the fed state, that is why the drug has to be taken after a high fat meal) .
- Exposure was 1.25-times higher than the reference exposure.
- C max was somewhat lower for the complex Ivacaftor formulation, however, for the more important parameter, C 24h , the complex Ivacaftor was 1.4-times higher ( Figure 25 and Figure 26) .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1600271A HUP1600271A2 (en) | 2016-04-25 | 2016-04-25 | Pharmaceutical composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them |
PCT/IB2017/052374 WO2017187340A1 (en) | 2016-04-25 | 2017-04-25 | Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3448384A1 true EP3448384A1 (en) | 2019-03-06 |
Family
ID=89992149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17726698.8A Withdrawn EP3448384A1 (en) | 2016-04-25 | 2017-04-25 | Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3448384A1 (en) |
JP (1) | JP2019514898A (en) |
CN (1) | CN109475546A (en) |
AU (1) | AU2017256184A1 (en) |
CA (1) | CA3022203A1 (en) |
HU (1) | HUP1600271A2 (en) |
IL (1) | IL262494A (en) |
WO (1) | WO2017187340A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019232306A1 (en) | 2018-05-31 | 2019-12-05 | Celtaxsys, Inc. | Method of reducing pulmonary exacerbations in respiratory disease patients |
WO2023044365A1 (en) * | 2021-09-17 | 2023-03-23 | Doublerainbow Biosciences Inc. | Use of cyclodextrin to enhance solubility of substrates and increase enzymatic glycosylation reaction efficiency |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ587551A (en) | 2004-06-24 | 2012-01-12 | Vertex Pharma | 5-Amino-phenol derivatives such as 5-amino-2,4-di-tert-butyl-phenol |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
EP3696174A1 (en) | 2005-11-08 | 2020-08-19 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of atp-binding cassette transporters |
PL3219705T3 (en) | 2005-12-28 | 2020-08-10 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
CN103626744B (en) | 2007-12-07 | 2016-05-11 | 沃泰克斯药物股份有限公司 | The benzoic solid form of 3-(6-(1-(2,2-difluoro benzo [D] [1,3] dioxole-5-yl) cyclopropane formamido group)-3-picoline-2-yl) |
EA201070699A1 (en) | 2007-12-07 | 2011-02-28 | Вертекс Фармасьютикалз Инкорпорейтед | COMPOSITIONS 3- (6- (1-2,2-DIFTORBENZO [D] [1,3] DIOXOL-5-IL) CYCLOPROPANKARAROXAMIDO) -3-Methylpyridine-2-il |
WO2010037066A2 (en) | 2008-09-29 | 2010-04-01 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
CA2794559C (en) | 2010-03-25 | 2019-07-23 | Vertex Pharmaceuticals Incorporated | Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide |
WO2011127241A2 (en) | 2010-04-07 | 2011-10-13 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof |
RS54783B1 (en) | 2010-04-07 | 2016-10-31 | Vertex Pharma | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
WO2012027731A2 (en) | 2010-08-27 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
EP2806859B1 (en) | 2012-01-25 | 2019-05-15 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
CN109966264A (en) | 2012-02-27 | 2019-07-05 | 沃泰克斯药物股份有限公司 | Pharmaceutical composition and its application |
CA2878057A1 (en) | 2012-07-16 | 2014-01-23 | Rossitza Gueorguieva Alargova | Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
NZ708474A (en) | 2012-11-02 | 2019-02-22 | Vertex Pharma | Pharmaceutical compositions for the treatment of cftr mediated diseases |
JP6146990B2 (en) | 2012-11-16 | 2017-06-14 | コンサート ファーマシューティカルズ インコーポレイテッド | Deuterated CFTR enhancer |
US20140221424A1 (en) | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
WO2014118805A1 (en) | 2013-01-31 | 2014-08-07 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for the preparation of ivacaftor and solvates thereof |
US9573902B2 (en) | 2013-02-15 | 2017-02-21 | Laurus Labs Private Ltd. | Process for the preparation of Ivacaftor and its intermediates |
CN104030981A (en) | 2013-03-06 | 2014-09-10 | 上海特化医药科技有限公司 | Preparation method and intermediate of Ivacaftor |
WO2015071841A1 (en) * | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
KR102280372B1 (en) | 2013-11-12 | 2021-07-22 | 버텍스 파마슈티칼스 인코포레이티드 | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
HUP1300646A2 (en) * | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
HUP1300647A2 (en) * | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of cyclosporine a and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
WO2015070336A1 (en) | 2013-11-13 | 2015-05-21 | Apotex Inc. | Solid forms of ivacaftor and processes for the preparation thereof |
HUP1400075A2 (en) * | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical composition containing them |
PL3925607T3 (en) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
WO2015175773A1 (en) | 2014-05-15 | 2015-11-19 | Celgene Corporation | Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis |
CN104725314A (en) | 2015-03-23 | 2015-06-24 | 上海皓元化学科技有限公司 | New crystal form of Ivacaftor and preparation method thereof |
-
2016
- 2016-04-25 HU HU1600271A patent/HUP1600271A2/en unknown
-
2017
- 2017-04-25 EP EP17726698.8A patent/EP3448384A1/en not_active Withdrawn
- 2017-04-25 JP JP2018555738A patent/JP2019514898A/en not_active Withdrawn
- 2017-04-25 CN CN201780039649.6A patent/CN109475546A/en active Pending
- 2017-04-25 CA CA3022203A patent/CA3022203A1/en not_active Abandoned
- 2017-04-25 WO PCT/IB2017/052374 patent/WO2017187340A1/en active Application Filing
- 2017-04-25 AU AU2017256184A patent/AU2017256184A1/en not_active Abandoned
-
2018
- 2018-10-21 IL IL262494A patent/IL262494A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN109475546A (en) | 2019-03-15 |
AU2017256184A1 (en) | 2018-12-13 |
WO2017187340A4 (en) | 2017-12-28 |
CA3022203A1 (en) | 2017-11-02 |
JP2019514898A (en) | 2019-06-06 |
IL262494A (en) | 2018-12-31 |
HUP1600271A2 (en) | 2017-10-30 |
WO2017187340A1 (en) | 2017-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200022969A1 (en) | Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them | |
US10675277B2 (en) | Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
ES2857152T3 (en) | Pharmaceutical composition and administrations thereof | |
US20210228489A1 (en) | Compositions for treating cystic fibrosis | |
KR20150082203A (en) | Formulations of enzalutamide | |
US10688110B2 (en) | Complexes of Celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
US20200061058A1 (en) | Pharmaceutical formulation containing tadalafil | |
EP3448384A1 (en) | Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them | |
US20190388408A1 (en) | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
WO2017187336A1 (en) | Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
WO2017187338A1 (en) | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
WO2015199115A1 (en) | Pharmaceutical composition for oral administration | |
KR101956586B1 (en) | Pharmaceutical composition and preparation method thereof | |
JP2004307377A (en) | Itraconazole composition having improved absorbability and used for oral administration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20181120 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GLAVINAS, HRISTOS Inventor name: PATYI, GERGOE Inventor name: FILIPCSEI, GENOVEVA Inventor name: SZABONE ORDASI, BETTI Inventor name: ANGI, ERZSEBET REKA Inventor name: BASA-DENES, ORSOLYA Inventor name: KARPATI, RICHARD BALAZS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40005616 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20200417 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20210112 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20210526 |